| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 210 | 320 | 33,820 | 1,980 | 5,370 |
| Sales Growth | -34.38% | -99.05% | +1,608.08% | -63.13% | -57.11% |
| Net Income | -88,390 | -82,100 | 172,170 | -173,240 | -43,520 |
| Net Income Growth | -7.66% | -147.69% | +199.38% | -298.07% | +61.34% |
Chimerix Inc (CMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Chimerix is a biopharmaceutical company which develop medicines for lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program ONC201, is in development for H3 K27M-mutant glioma. Chimerix is based in DURHAM, N.C.
Fiscal Year End Date: 12/31